Skip to main content

home

OVERVIEW
Our unique Guangzhou-Israel Biotechnology Fund (GIBF) creates added value for Israeli, European and American companies looking to expand in China.

With years of life sciences expertise, private equity investment experience, local knowledge based on over a decade of activity in China, and numerous foreign companies already established in China, GIBF serves as an invaluable strategic investor and partner in China with a proven ability and track record of conducting multi-center clinical trials in top-tier Chinese hospitals, providing the resources and networks for securing successful NMPA submissions, commercializing products and developing manufacturing capacity to satisfy both local and global demand.

OUR STRATEGY
Enabling value creation by investing in Chinese subsidiaries of foreign companies active in the biomedical outside China
GIBF partners with selected companies from Israel, Europe and the USA to establish new JVs in the Chinese market, enabling the foreign companies to control and manage their new subsidiaries as the majority shareholders.
PORTFOLIO
Companies' Overview
Partnering with top-tier international life sciences companies offering innovative solutions to Chinese healthcare needs.

COMPANY

InMode (NASDAQ: INMD) (Exit)

SECTOR

Medical Device

COMPANY

G-Medical (NASDAQ: GMVD)

SECTOR

Medical Device

COMPANY

CarboFix

SECTOR

Medical Device
OUR PEOPLE
Meet Our Management
Where global leaders in life sciences meet local talents to achieve cross-border investments and companies' formation.
DR. YEHOSHUA(SHUKI) GLEITMAN
Founding Partner and Chairman
PROF. SHLOMO NOY
Founding Partner and Chief Medical Officer
AVNER LUSHI
Founding Partner and CEO
CARL GENG
Founding Partner and General Manager
Latest
News

VIEW ALL

Latest
News
nectin(for news)

GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates

(6 May, 2024) Guangzhou-Israel Biotechnology Fund (GIBF) announced today that it has invested $10 million in Nectin Therapeutics Ltd, proceeds from financing to support ongoing clinical development of lead program targeting PVR as well as IND-enabling activities for multiple ADC candidates.

投资组合向右箭头
nectin EIC news

Breaking news - Nectin winning the EIC funding

(18 March, 2024) Nectin Therapeutics Ltd. (" Nectin "), the parent company of Guangzhou Nectin Pharma Ltd. has been selected as one of the 42 recipients of EIC funding in the 2023 EIC Accelerator from a competitive field of 1,083 proposals and 242 companies that were reviewed.

投资组合向右箭头
shuki-外交特别贡献奖

Dr. Shuki Gleitman receives Certificates of Appreciation from Israeli Foreign Affairs

(25 Dec, 2023) Israeli Foreign Affairs Minister Mr. Eli Cohen awarded certificates of appreciation to businessmen and organizations for their contribution to Israel's foreign relations and strengthening its global position.

投资组合向右箭头